Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 220

1.

Decreased Physical Working Capacity in Adolescents With Non-Alcoholic Fatty Liver Disease Associates With Reduced Iron Availability: PWC in NAFLD Relates to Iron Bioavailability.

Mitchell T, McKinnon E, Ayonrinde O, Adams LA, Trinder D, Chua ACG, Newton RU, Straker L, Olynyk JK.

Clin Gastroenterol Hepatol. 2019 Oct 16. pii: S1542-3565(19)31116-4. doi: 10.1016/j.cgh.2019.10.017. [Epub ahead of print]

PMID:
31628998
2.

Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials.

Pai RK, Kleiner DE, Hart J, Adeyi OA, Clouston AD, Behling CA, Jain D, Kakar S, Brahmania M, Burgart L, Batts KP, Valasek MA, Torbenson MS, Guindi M, Wang HL, Ajmera V, Adams LA, Parker CE, Feagan BG, Loomba R, Jairath V.

Aliment Pharmacol Ther. 2019 Oct 3. doi: 10.1111/apt.15503. [Epub ahead of print]

PMID:
31583739
3.

Editorial: The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis due to NASH.

Loomba R, Adams LA.

Hepatology. 2019 Sep 13. doi: 10.1002/hep.30946. [Epub ahead of print]

PMID:
31520407
4.

Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.

Chen F, Esmaili S, Rogers G, Bugianesi E, Petta S, Marchesini G, Bayoumi A, Metwally M, Azardaryany MK, Coulter S, Choo JM, Younes R, Rosso C, Liddle C, Adams LA, Craxì A, George J, Eslam M.

Hepatology. 2019 Aug 23. doi: 10.1002/hep.30908. [Epub ahead of print]

PMID:
31442319
5.

Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy.

Wallace MC, Sek K, Francis RJ, Samuelson S, Ferguson J, Tibballs J, Asad A, Preen DB, MacQuillan G, Garas G, Adams LA, Jeffrey GP.

Dig Dis Sci. 2019 Aug 22. doi: 10.1007/s10620-019-05781-6. [Epub ahead of print]

PMID:
31440998
6.

Effects of calcium supplementation on circulating osteocalcin and glycated haemoglobin in older women.

Lewis JR, Brennan-Speranza TC, Levinger I, Byrnes E, Lim EM, Blekkenhorst LC, Sim M, Hodgson JM, Zhu K, Lim WH, Adams LA, Prince RL.

Osteoporos Int. 2019 Oct;30(10):2065-2072. doi: 10.1007/s00198-019-05087-3. Epub 2019 Jul 24.

PMID:
31342138
7.

Long-term Liver-related Outcomes of Patients with Chronic Liver Diseases in Australia.

Huang Y, Joseph J, de Boer WB, Cheng W, Adams LA, MacQuillan G, Garas G, Raftopoulos S, Jeffrey GP.

Clin Gastroenterol Hepatol. 2019 Jul 15. pii: S1542-3565(19)30746-3. doi: 10.1016/j.cgh.2019.07.013. [Epub ahead of print]

PMID:
31319186
8.

Correction to: End-points for drug treatment in NASH.

Adams LA.

Hepatol Int. 2019 May;13(3):259. doi: 10.1007/s12072-019-09949-0. Epub 2019 May 9.

PMID:
31073971
9.

Bowel patterns, gastrointestinal symptoms, and emotional well-being in adolescents: A cohort study.

Ayonrinde OT, Sanfilippo FM, O'Sullivan TA, Adams LA, Ayonrinde OA, Robinson M, Oddy WH, Olynyk JK.

J Gastroenterol Hepatol. 2019 May 6. doi: 10.1111/jgh.14699. [Epub ahead of print]

PMID:
31059144
10.

Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.

Bertot LC, Adams LA.

Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):179-187. doi: 10.1080/17474124.2019.1549989. Epub 2018 Dec 29. Review.

PMID:
30791782
11.

End-points for drug treatment in NASH.

Adams LA.

Hepatol Int. 2019 May;13(3):253-258. doi: 10.1007/s12072-019-09935-6. Epub 2019 Feb 19. Review. Erratum in: Hepatol Int. 2019 May 9;:.

PMID:
30783901
12.

Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand.

Calzadilla-Bertot L, Jeffrey GP, Jacques B, McCaughan G, Crawford M, Angus P, Jones R, Gane E, Munn S, Macdonald G, Fawcett J, Wigg A, Chen J, Fink M, Adams LA.

Liver Transpl. 2019 Jan;25(1):25-34. doi: 10.1002/lt.25361.

PMID:
30609187
13.

Features of the metabolic syndrome in late adolescence are associated with impaired testicular function at 20 years of age.

Hart RJ, Doherty DA, Mori TA, Adams LA, Huang RC, Minaee N, Handelsman DJ, McLachlan R, Norman RJ, Dickinson JE, Olynyk JK, Beilin LJ.

Hum Reprod. 2019 Mar 1;34(3):389-402. doi: 10.1093/humrep/dey371.

PMID:
30576537
14.

Fibroblast growth factor 21 for non-alcoholic steatohepatitis.

Wong VWS, Adams LA.

Lancet. 2019 Dec 22;392(10165):2658-2660. doi: 10.1016/S0140-6736(18)32165-2. Epub 2018 Dec 13. No abstract available.

PMID:
30554786
15.

A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR.

Metwally M, Bayoumi A, Romero-Gomez M, Thabet K, John M, Adams LA, Huo X, Aller R, García-Monzón C, Teresa Arias-Loste M, Bugianesi E, Miele L, Gallego-Durán R, Fischer J, Berg T, Liddle C, Qiao L, George J, Eslam M.

J Hepatol. 2019 Mar;70(3):494-500. doi: 10.1016/j.jhep.2018.10.021. Epub 2018 Oct 31.

PMID:
30389552
16.

Liver Transplantation in Adults With Liver Disease Due to Common Variable Immunodeficiency Leads to Early Recurrent Disease and Poor Outcome.

Ramlaul N, Ooi J, Jeffrey GP, MacQuillan G, Garas G, Adams LA, Iqbal M, Nolan N, Houlihan DD, McCormick PA, Mac Nicholas R.

Liver Transpl. 2018 Nov;24(11):1622-1626. doi: 10.1002/lt.25343. No abstract available.

PMID:
30260552
17.

Hepatocellular carcinoma in Australia 1982-2014: Increasing incidence and improving survival.

Wallace MC, Preen DB, Short MW, Adams LA, Jeffrey GP.

Liver Int. 2019 Mar;39(3):522-530. doi: 10.1111/liv.13966. Epub 2018 Nov 5.

PMID:
30230194
18.

Small neutral Gd(iii) tags for distance measurements in proteins by double electron-electron resonance experiments.

Mahawaththa MC, Lee MD, Giannoulis A, Adams LA, Feintuch A, Swarbrick JD, Graham B, Nitsche C, Goldfarb D, Otting G.

Phys Chem Chem Phys. 2018 Sep 19;20(36):23535-23545. doi: 10.1039/c8cp03532f.

PMID:
30183028
19.

ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis.

Daniels SJ, Leeming DJ, Eslam M, Hashem AM, Nielsen MJ, Krag A, Karsdal MA, Grove JI, Neil Guha I, Kawaguchi T, Torimura T, McLeod D, Akiba J, Kaye P, de Boer B, Aithal GP, Adams LA, George J.

Hepatology. 2019 Mar;69(3):1075-1086. doi: 10.1002/hep.30163.

PMID:
30014517
20.

Type and Pattern of Alcohol Consumption is Associated With Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease.

Mitchell T, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Ching H, Hamdorf J, Adams LA.

Am J Gastroenterol. 2018 Oct;113(10):1484-1493. doi: 10.1038/s41395-018-0133-5. Epub 2018 Jun 14.

PMID:
29899440
21.

Site-Specific Incorporation of Selenocysteine by Genetic Encoding as a Photocaged Unnatural Amino Acid.

Welegedara AP, Adams LA, Huber T, Graham B, Otting G.

Bioconjug Chem. 2018 Jul 18;29(7):2257-2264. doi: 10.1021/acs.bioconjchem.8b00254. Epub 2018 Jun 21.

PMID:
29874064
22.

Burden of non-alcoholic fatty liver disease in Australia.

Mahady SE, Adams LA.

J Gastroenterol Hepatol. 2018 Jun;33 Suppl 1:1-11. doi: 10.1111/jgh.14270.

PMID:
29851153
23.

Noninvasive biomarkers in NAFLD and NASH - current progress and future promise.

Wong VW, Adams LA, de Lédinghen V, Wong GL, Sookoian S.

Nat Rev Gastroenterol Hepatol. 2018 Aug;15(8):461-478. doi: 10.1038/s41575-018-0014-9. Review.

PMID:
29844588
24.

The Prognostic Ability of Major Hepatocellular Carcinoma Staging Systems Is Improved by Including a Treatment Variable.

Wallace MC, Knuiman M, Huang Y, Garas G, Adams LA, MacQuillan G, Preen DB, Jeffrey GP.

Dig Dis Sci. 2018 Sep;63(9):2277-2284. doi: 10.1007/s10620-018-5132-2. Epub 2018 May 28.

PMID:
29808245
25.

Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.

Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, Eslam M, Gonzalez-Fabian L, Alvarez-Quiñones Sanz M, Conde-Martin AF, De Boer B, McLeod D, Hung Chan AW, Chalasani N, George J, Adams LA, Romero-Gomez M.

Gastroenterology. 2018 Aug;155(2):443-457.e17. doi: 10.1053/j.gastro.2018.04.034. Epub 2018 May 5.

PMID:
29733831
26.

Ad Libitum Mediterranean and Low-Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial.

Properzi C, O'Sullivan TA, Sherriff JL, Ching HL, Jeffrey GP, Buckley RF, Tibballs J, MacQuillan GC, Garas G, Adams LA.

Hepatology. 2018 Nov;68(5):1741-1754. doi: 10.1002/hep.30076. Epub 2018 Oct 14.

PMID:
29729189
27.

Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.

Bertot LC, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Chin J, Huang Y, Adams LA.

Liver Int. 2018 Oct;38(10):1793-1802. doi: 10.1111/liv.13739. Epub 2018 Mar 31.

PMID:
29575516
28.

Trimethylsilyl tag for probing protein-ligand interactions by NMR.

Becker W, Adams LA, Graham B, Wagner GE, Zangger K, Otting G, Nitsche C.

J Biomol NMR. 2018 Apr;70(4):211-218. doi: 10.1007/s10858-018-0173-6. Epub 2018 Mar 21.

PMID:
29564580
29.

Prevalence of restless legs syndrome in a tertiary cohort of ambulant patients with chronic liver disease.

Ma MX, Huang Y, Adams LA, Gilpin R, Garas G, MacQuillan G, Jeffrey GP, Nicholas RM.

Intern Med J. 2018 Mar;48(3):347-350. doi: 10.1111/imj.13719.

PMID:
29512318
30.

Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma.

Bertot LC, Jeffrey GP, Wallace M, MacQuillan G, Garas G, Ching HL, Adams LA.

Hepatol Commun. 2017 Feb 27;1(1):53-60. doi: 10.1002/hep4.1018. eCollection 2017 Feb.

31.

Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus.

Hamdouchi C, Maiti P, Warshawsky AM, DeBaillie AC, Otto KA, Wilbur KL, Kahl SD, Patel Lewis A, Cardona GR, Zink RW, Chen K, Cr S, Lineswala JP, Neathery GL, Bouaichi C, Diseroad BA, Campbell AN, Sweetana SA, Adams LA, Cabrera O, Ma X, Yumibe NP, Montrose-Rafizadeh C, Chen Y, Miller AR.

J Med Chem. 2018 Feb 8;61(3):934-945. doi: 10.1021/acs.jmedchem.7b01411. Epub 2018 Jan 5.

PMID:
29236497
32.

Genetically encoded amino acids with tert-butyl and trimethylsilyl groups for site-selective studies of proteins by NMR spectroscopy.

Loh CT, Adams LA, Graham B, Otting G.

J Biomol NMR. 2018 Aug;71(4):287-293. doi: 10.1007/s10858-017-0157-y. Epub 2017 Dec 2.

PMID:
29197976
33.

Selective Distance Measurements Using Triple Spin Labeling with Gd3+, Mn2+, and a Nitroxide.

Wu Z, Feintuch A, Collauto A, Adams LA, Aurelio L, Graham B, Otting G, Goldfarb D.

J Phys Chem Lett. 2017 Nov 2;8(21):5277-5282. doi: 10.1021/acs.jpclett.7b01739. Epub 2017 Oct 13.

PMID:
28990781
34.

Rate of Nonsurveillance and Advanced Hepatocellular Carcinoma at Diagnosis in Chronic Liver Disease.

Huang Y, Wallace MC, Adams LA, MacQuillan G, Garas G, Ferguson J, Samuelson S, Tibballs J, Jeffrey GP.

J Clin Gastroenterol. 2018 Jul;52(6):551-556. doi: 10.1097/MCG.0000000000000916.

PMID:
28858944
35.

A community-academic partnership to explore informational needs of African American women as a primer for cancer clinical trial recruitment.

Rivers DA, Pal T, Vadaparampil ST, Adams LA, Dash-Pitts L, Quinn GP.

Ethn Health. 2019 Aug;24(6):679-693. doi: 10.1080/13557858.2017.1367762. Epub 2017 Aug 22.

PMID:
28826243
36.

Chemical Tagging with tert-Butyl and Trimethylsilyl Groups for Measuring Intermolecular Nuclear Overhauser Effects in a Large Protein-Ligand Complex.

Jabar S, Adams LA, Wang Y, Aurelio L, Graham B, Otting G.

Chemistry. 2017 Sep 21;23(53):13033-13036. doi: 10.1002/chem.201703531. Epub 2017 Aug 18.

PMID:
28763128
37.

Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome.

Jeffrey AW, Huang Y, de Boer WB, Adams LA, MacQuillan G, Speers D, Joseph J, Jeffrey GP.

World J Hepatol. 2017 Jul 8;9(19):850-856. doi: 10.4254/wjh.v9.i19.850.

38.

Two functionally distinct NADP+-dependent ferredoxin oxidoreductases maintain the primary redox balance of Pyrococcus furiosus.

Nguyen DMN, Schut GJ, Zadvornyy OA, Tokmina-Lukaszewska M, Poudel S, Lipscomb GL, Adams LA, Dinsmore JT, Nixon WJ, Boyd ES, Bothner B, Peters JW, Adams MWW.

J Biol Chem. 2017 Sep 1;292(35):14603-14616. doi: 10.1074/jbc.M117.794172. Epub 2017 Jul 13.

39.

Sex differences between parental pregnancy characteristics and nonalcoholic fatty liver disease in adolescents.

Ayonrinde OT, Adams LA, Mori TA, Beilin LJ, de Klerk N, Pennell CE, White S, Olynyk JK.

Hepatology. 2018 Jan;67(1):108-122. doi: 10.1002/hep.29347. Epub 2017 Nov 13.

PMID:
28665032
40.

The Raine study had no evidence of significant perinatal selection bias after two decades of follow up: a longitudinal pregnancy cohort study.

White SW, Eastwood PR, Straker LM, Adams LA, Newnham JP, Lye SJ, Pennell CE.

BMC Pregnancy Childbirth. 2017 Jun 29;17(1):207. doi: 10.1186/s12884-017-1391-8.

41.

Infant nutrition and maternal obesity influence the risk of non-alcoholic fatty liver disease in adolescents.

Ayonrinde OT, Oddy WH, Adams LA, Mori TA, Beilin LJ, de Klerk N, Olynyk JK.

J Hepatol. 2017 Sep;67(3):568-576. doi: 10.1016/j.jhep.2017.03.029. Epub 2017 Jun 12.

PMID:
28619255
42.

HKLC Triages More Hepatocellular Carcinoma Patients to Curative Therapies Compared to BCLC and Is Associated with Better Survival.

Wallace MC, Huang Y, Preen DB, Garas G, Adams LA, MacQuillan G, Tibballs J, Ferguson J, Samuelson S, Jeffrey GP.

Dig Dis Sci. 2017 Aug;62(8):2182-2192. doi: 10.1007/s10620-017-4622-y. Epub 2017 May 25.

PMID:
28547649
43.

Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH.

Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, Gra-Oramas B, Gonzalez-Fabian L, Lazo-Del Vallin S, Diago M, Adams LA.

Liver Int. 2017 Dec;37(12):1887-1896. doi: 10.1111/liv.13480. Epub 2017 Jun 14.

PMID:
28544769
44.

Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice.

Cartland SP, Harith HH, Genner SW, Dang L, Cogger VC, Vellozzi M, Di Bartolo BA, Thomas SR, Adams LA, Kavurma MM.

Sci Rep. 2017 May 15;7(1):1898. doi: 10.1038/s41598-017-01721-4.

45.

Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.

Adams LA, Anstee QM, Tilg H, Targher G.

Gut. 2017 Jun;66(6):1138-1153. doi: 10.1136/gutjnl-2017-313884. Epub 2017 Mar 17. Review.

PMID:
28314735
46.

Developing a new algorithm to diagnose advanced liver fibrosis: A lift or a nudge in the right direction?

Adams LA, Sterling RK.

J Hepatol. 2017 Jun;66(6):1111-1113. doi: 10.1016/j.jhep.2017.02.011. Epub 2017 Feb 17. No abstract available.

PMID:
28219771
47.

Transjugular intrahepatic portosystemic shunt: Indications, complications, survival and its use as a bridging therapy to liver transplant in Western Australia.

Pateria P, Jeffrey GP, Garas G, Tibballs J, Ferguson J, Delriviere L, Huang Y, Adams LA, MacQuillan G.

J Med Imaging Radiat Oncol. 2017 Aug;61(4):441-447. doi: 10.1111/1754-9485.12563. Epub 2017 Jan 9.

PMID:
28070962
48.

Effect of airplane transport of donor livers on post-liver transplantation survival.

Huang Y, MacQuillan G, Adams LA, Garas G, Collins M, Nwaba A, Mou L, Bulsara MK, Delriviere L, Jeffrey GP.

World J Gastroenterol. 2016 Nov 7;22(41):9154-9161.

49.

Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis.

Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, Gra-Oramas B, Gonzalez-Fabian L, Villa-Jimenez O, Lazo-Del Vallin S, Diago M, Adams LA, Romero-Gomez M, Chalasani N.

Aliment Pharmacol Ther. 2017 Jan;45(2):332-344. doi: 10.1111/apt.13860. Epub 2016 Nov 16.

50.

Serum models accurately predict liver-related clinical outcomes in chronic hepatitis C.

Huang Y, Adams LA, MacQuillan G, Speers D, Joseph J, Bulsara MK, Jeffrey GP.

J Gastroenterol Hepatol. 2016 Oct;31(10):1736-1741. doi: 10.1111/jgh.13333.

PMID:
26945918

Supplemental Content

Loading ...
Support Center